相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A. Ascierto et al.
EUROPEAN JOURNAL OF CANCER (2020)
Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
Dimitrios C. Ziogas et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.
Paolo Antonio Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
Sandra Huynh et al.
CANCERS (2020)
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
P. Nathan et al.
ANNALS OF ONCOLOGY (2020)
First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
P. A. Ascierto et al.
ANNALS OF ONCOLOGY (2020)
Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
A. M. Arance Fernandez et al.
ANNALS OF ONCOLOGY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma A Review
Reinhard Dummer et al.
JAMA ONCOLOGY (2020)
Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma
Florentia Dimitriou et al.
JOURNAL OF IMMUNOTHERAPY (2019)
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Bastian Schilling et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1312PDSafety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study
E M Burton et al.
ANNALS OF ONCOLOGY (2019)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long et al.
ANNALS OF ONCOLOGY (2019)
Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
Anna M. Czarnecka et al.
TARGETED ONCOLOGY (2019)
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors
Daniela Massi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Tolerance and Efficacy of BRAF Plus MEK Inhibition in Patients With Melanoma Who Previously Have Received Programmed Cell Death Protein 1-Based Therapy
Karim R. Saab et al.
CANCER (2019)
Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patientsreal-world data
Marta Polkowska et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
Meredith S. Pelster et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France
B. Sassolas et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
Natalia Pieper et al.
ONCOIMMUNOLOGY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Alexandra Frazao et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Shannon M. Steinberg et al.
CANCER RESEARCH (2017)
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
Blanca Homet Moreno et al.
ONCOIMMUNOLOGY (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Marcel A. Deken et al.
ONCOIMMUNOLOGY (2016)
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A. Cooper et al.
ONCOIMMUNOLOGY (2016)
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
Hojabr Kakavand et al.
CLINICAL CANCER RESEARCH (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R. Minor et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Sherille D. Bradley et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Allison Ackerman et al.
CANCER (2014)
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Paolo Antonio Ascierto et al.
CANCER INVESTIGATION (2014)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
Lucas Ferrari de Andrade et al.
CANCER RESEARCH (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Shannon M. Steinberg et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
Patrick A. Ott et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Melanoma - An Unlikely Poster Child for Personalized Cancer Therapy
Keiran S. M. Smalley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
